导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -29.75% | 4726/4766 |
| 近一周 | -3.42% | 4926/5457 |
| 近一月 | -5.71% | 2569/5411 |
| 近一季 | -4.45% | 1615/5229 |
| 近半年 | -27.80% | 4874/4923 |
| 近一年 | -35.87% | 4342/4393 |
| 近两年 | -27.71% | 2947/2948 |
| 近三年 | -59.61% | 2247/2248 |
| 成立以来 | -50.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-13.44% 4610/4961 |
-22.37% 4912/5312 |
- - |
- - |
| 2025 | -11.04% 3393/4813 |
-6.08% 3336/3635 |
-4.59% 3483/4076 |
9.97% 3326/4524 |
-9.72% 4086/4813 |
| 2024 | -14.33% 2437/3463 |
-10.27% 2331/2808 |
-13.69% 2641/3014 |
31.17% 113/3129 |
-15.66% 3082/3463 |
| 2023 | -36.90% 2142/2656 |
-9.36% 2184/2280 |
-7.28% 1827/2385 |
-3.96% 1025/2515 |
-21.82% 2497/2655 |
| 2022 | -13.67% 336/2207 |
8.03% 20/1919 |
-8.16% 1894/2016 |
-9.22% 259/2113 |
-4.15% 1885/2208 |
| 2021 | -10.92% 1099/1822 |
-1.61% 522/1255 |
-9.10% 1284/1330 |
2.70% 430/1466 |
-3.02% 1432/1822 |
| 2020 | -7.19% 987/1250 |
-14.21% 952/1028 |
5.01% 893/1067 |
9.14% 668/1164 |
-5.60% 1138/1184 |
| 2019 | 47.78% 117/1092 |
38.22% 67/754 |
-9.89% 700/804 |
0.88% 449/850 |
17.62% 13/918 |
| 2018 | -21.62% 217/834 |
- - |
- - |
- - |
-5.42% 33/691 |
| 2017 | 12.74% 272/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.63% 361/605 |
- - |
- - |
- - |
- - |
| 2015 | 16.14% 135/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 招商沪深300地产等权重指数A VS. 长安沪深300非周期A(740101) |